Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

SAB Biotherapeutics (SABS) EBIT Margin (2021 - 2024)

SAB Biotherapeutics filings provide 4 years of EBIT Margin readings, the most recent being 8726.26% for Q4 2024.

  • On a quarterly basis, EBIT Margin fell 253836.0% to 8726.26% in Q4 2024 year-over-year; TTM through Dec 2024 was 3244.87%, a 154432.0% decrease, with the full-year FY2024 number at 3244.87%, down 154432.0% from a year prior.
  • EBIT Margin hit 8726.26% in Q4 2024 for SAB Biotherapeutics, down from 3876.95% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 792.62% in Q4 2022 to a low of 8726.26% in Q4 2024.
  • Median EBIT Margin over the past 4 years was 217.49% (2022), compared with a mean of 1930.23%.
  • Biggest five-year swings in EBIT Margin: tumbled -747037bps in 2023 and later surged 369644bps in 2024.
  • SAB Biotherapeutics' EBIT Margin stood at 66.41% in 2021, then soared by 1293bps to 792.62% in 2022, then crashed by -881bps to 6187.9% in 2023, then plummeted by -41bps to 8726.26% in 2024.
  • The last three reported values for EBIT Margin were 8726.26% (Q4 2024), 3876.95% (Q2 2024), and 1205.9% (Q1 2024) per Business Quant data.